Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB201 vs GB201 + FOLFIRI in metastatic colorectal cancer after standard therapy failure
CTR20171559Phase 3Active
- Sponsor
- Strong Biotechnologies
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of napabucasin in colorectal cancer (CRC), sponsored by Strong Biotechnologies. Started Apr 2018; status: active.
02
Drugs
napabucasin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20171559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171559.